Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $81.67 Consensus Target Price from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $81.6667.

Several brokerages recently issued reports on ARWR. Bank of America boosted their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Morgan Stanley raised their price objective on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Chardan Capital lifted their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. The Goldman Sachs Group upped their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. Finally, Royal Bank Of Canada raised their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $56.71 on Thursday. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $76.76. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The firm’s 50-day simple moving average is $63.90 and its 200 day simple moving average is $52.10. The firm has a market cap of $7.94 billion, a price-to-earnings ratio of 37.07 and a beta of 1.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. During the same period in the prior year, the firm earned ($1.39) EPS. The business’s revenue for the quarter was up 10461.3% on a year-over-year basis. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 10,040 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $67.68, for a total value of $679,507.20. Following the sale, the director owned 35,723 shares of the company’s stock, valued at approximately $2,417,732.64. This trade represents a 21.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Adeoye Y. Olukotun sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the completion of the transaction, the director owned 33,600 shares in the company, valued at approximately $2,273,376. The trade was a 22.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 226,538 shares of company stock valued at $14,967,942 over the last three months. 3.60% of the stock is owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently bought and sold shares of the business. Marex Group plc bought a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth about $576,000. Nordea Investment Management AB boosted its holdings in Arrowhead Pharmaceuticals by 74.5% in the third quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock valued at $12,661,000 after acquiring an additional 158,937 shares during the last quarter. Marshall Wace LLP boosted its holdings in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares during the last quarter. HBK Sorce Advisory LLC acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $2,823,000. Finally, Erste Asset Management GmbH increased its position in Arrowhead Pharmaceuticals by 55.3% during the 3rd quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company’s stock valued at $2,466,000 after purchasing an additional 26,000 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.